Sernova (OTCPK:SEOV.F) - Stock Price, News & Analysis

SEOV.F Stock Overview

Operates as a clinical-stage regenerative medicine therapeutics company in Canada. More details

SEOV.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings are forecast to grow 61.39% per year

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap ($75M)

Volatile share price over the past 3 months compared to the US market

Sernova Corp. Competitors

Connect Biopharma Holdings

NasdaqGM:CNTB

US$55.3m

Vor Biopharma

NasdaqGS:VOR

US$54.3m

Unicycive Therapeutics

NasdaqCM:UNCY

US$55.0m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Price History & Performance

Summary of all time highs, changes and price drops for Sernova
Historical stock prices
Current Share Price	CA$0.16
52 Week High	CA$0.59
52 Week Low	CA$0.15
Beta	1.32
11 Month Change	-12.86%
3 Month Change	-10.67%
1 Year Change	-70.18%
33 Year Change	-84.78%
5 Year Change	7.04%
Change since IPO	-30.37%

Recent updates

Shareholder Returns

	SEOV.F	US Biotechs	US Market
7D	-3.9%	2.5%	2.2%
1Y	-70.2%	16.1%	31.6%

Return vs Industry: SEOV.F underperformed the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: SEOV.F underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is SEOV.F's price volatile compared to industry and market?
SEOV.F volatility
SEOV.F Average Weekly Movement	10.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SEOV.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SEOV.F's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1998	n/a	n/a	www.sernova.com

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs.

Sernova Corp. Fundamentals Summary

How do Sernova's earnings and revenue compare to its market cap?
SEOV.F fundamental statistics
Market cap	US$53.53m
Earnings (TTM)	-US$27.85m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Is SEOV.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SEOV.F income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$38.93m
Earnings	-CA$38.93m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.12
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SEOV.F perform over the long term?

See historical performance and comparison

SEOV.F Stock Overview

Rewards

Risk Analysis

Sernova Corp. Competitors

NasdaqGM:CNTB

US$55.3m

NasdaqGS:VOR

US$54.3m

NasdaqCM:UNCY

US$55.0m

NasdaqGS:FIXX

US$54.3m

Price History & Performance

Recent News & Updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Shareholder Returns

Price Volatility

About the Company

Sernova Corp. Fundamentals Summary

0.0x

-1.9x

Earnings & Revenue